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Abstract: Tendon and ligament injury poses an increasingly large burden to society. This system-
atic review explores whether mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) can
facilitate tendon/ligament repair in vivo. On 26 May 2021, a systematic search was performed on
PubMed, Web of Science, Cochrane Library, Embase, to identify all studies that utilised MSC-EVs for
tendon/ligament healing. Studies administering EVs isolated from human or animal-derived MSCs
into in vivo models of tendon/ligament injury were included. In vitro, ex vivo, and in silico studies
were excluded, and studies without a control group were excluded. Out of 383 studies identified,
11 met the inclusion criteria. Data on isolation, the characterisation of MSCs and EVs, and the in vivo
findings in in vivo models were extracted. All included studies reported better tendon/ligament
repair following MSC-EV treatment, but not all found improvements in every parameter measured.
Biomechanics, an important index for tendon/ligament repair, was reported by only eight stud-
ies, from which evidence linking biomechanical alterations to functional improvement was weak.
Nevertheless, the studies in this review showcased the safety and efficacy of MSC-EV therapy for
tendon/ligament healing, by attenuating the initial inflammatory response and accelerating tendon
matrix regeneration, providing a basis for potential clinical use in tendon/ligament repair.
Keywords: mesenchymal stem cells; extracellular vesicles; tendon; ligament; collagen; biomechan-
ics; macrophage
1. Introduction
Tendon and ligament injuries make up about 50% of all musculoskeletal injuries and
cost $30 billion a year to manage [1]. These can be due to underlying tendon diseases,
such as inflammatory or degenerative changes seen in tendinopathies, or due to acute
traumatic injury. Tendons generally have limited vascularisation when compared to muscle,
especially at the tendon–bone interface. There is reduced angiogenesis at these sites due
to inhibitory factors such as endostatin, secreted from neighbouring cells [2]. The blood
supply to tendons generally comes from three sources: the myotendinous junction, the
osteotendinous junction, and the tendon sheath. Ligaments, on the other hand, have
blood supply from the synovium as well as from the surrounding soft tissue. The healing
response in ligaments can be divided into the hemorrhagic, inflammatory, reparative,
and remodelling phases. The final phase can take up to months or years to complete,
and is subject to a number of external factors, with minimal exercise, smoking, and high
cholesterol associated with poorer outcomes [3]. These injuries can be severely debilitating,
whether in athletes trying to return to their high level of sporting ability, or patients
returning to independent living. Furthermore, a suboptimal healing process can cause scar
tissue formation, increasing the chance of reinjury [4].
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Traditional methods of tendon and ligament repair include suture anchors [5,6] and
autogenous tendon grafts [7]. When tendons are divided, the ends can be approximated
and sutured to promote healing. Complications such as adhesions [8], repair site gap
formation [9], or chondrolysis [10] may occur. Tissue grafting is another well-established
method of tendon repair. Autograft involves harvesting tissue from the patient’s own body
to replace the damaged tissue, and despite the success rate, complications such as donor
site morbidity issues or lack of adequate tissue may arise. Allograft and xenograft involve
tissue transplantation from a human or animal, respectively. These have greater availability
and flexibility but risk rejection, disease transmission, and zoonotic transmission [11].
In recent years, developments of stem cell therapies have created new avenues for
treatment [12]. Induced pluripotent (iPSC) and embryonic stem cells (ESCs) have the
highest differentiation capacity and flexibility; however the unlimited regenerative nature
of these cells can potentially increase the risk of teratoma development [13] or ectopic
bone formation [14]. Mesenchymal stem cells (MSCs) do not have the ethical concerns that
surround the use of ESCs but can potentially influence tumorigenesis and lead to cancer
treatment resistance [11]. These cells can be used in isolation or with appropriate biomate-
rial using a suitable scaffolding technique to create the most appropriate environment for
tissue regeneration. The purpose of an ideal scaffold should be to seamlessly transition
from the artificial alignment of the damaged tissue to the natural regeneration of native
tissue using the body’s inherent processes [15].
Recently, there has been a shift in the approach to cell-free therapy, with extracellular
components shown to have similar regenerative properties without the potentially harmful
effects of entire cell transplantations [16]. Extracellular vesicles (EVs) are extracellular
lipid membrane–bound particles that contain host cell-derived protein or nucleic acid
messengers, and have an effect on target cells via paracrine or autocrine regulatory func-
tions [17]. This new type of therapy has the potential to change the microenvironment of
healing tissue, reducing the inflammatory process and promoting regeneration, as shown
in various studies across different organ systems, such as neural [18], musculoskeletal [19],
and cardiac [20] tissues. This systematic review explores whether mesenchymal stem
cell-derived extracellular vesicles (MSC-EVs) can facilitate tendon/ligament repair in vivo.
2. Methodology
This review was carried out according to the 2020 Preferred Reporting Items for
Systematic Reviews and Meta Analyses (PRISMA) statement protocol [21]. An initial
review of the literature was performed to gauge the heterogeneity of the literature, after
which our search criteria were formulated. This lowered the chance that important studies
would be missed.
On 26 May 2021, a systematic search was performed on Embase, Medline, Web of
Science, and Cochrane Library, which were considered comprehensive. No filters of any
sort were used, and databases were searched from conception. The search strategy is
shown in Supplementary Table S1. All studies found by our search were imported into
Mendeley and deduplicated. VL and MT independently completed title and abstract
screening and agreement between authors was assessed and generated 93% agreement.
A third reviewer (WK) was contacted for unresolvable disagreements. Next, full-text
screening was performed by VL and MT, based on the inclusion and exclusion criteria
shown in Supplementary Table S2. Again, a third reviewer (WK) was consulted for
any disagreements. A ‘snowball’ search was then performed on 2 June 2021, whereby
references of the included studies as well as studies that cited any of the included studies
were independently searched by VL and MT, using Google Scholar to identify and screen
studies. Studies that performed in vivo experiments, using EVs isolated from human– or
animal–derived MSCs, were included. Studies that characterised their MSC population
using guidelines from the International Society for Cellular Therapy [22] and characterised
their EV population using International Society for Extracellular Vesicles (ISEV) standards
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were included [23]. In vitro, ex vivo, and in silico studies were excluded, and studies
without a control arm were excluded.
Data extraction was independently performed by VL and MT, with a third reviewer
(WK) to resolve disagreements. Data were extracted into data tables created in a standard-
ised excel spreadsheet for assessment of study quality and evidence synthesis. Data from
each study were split into 4 categories:
1. Isolation and characterisation of MSCs, including source of MSCs, cellular origin,
cell treatment to extract MSCs, and procedures to verify MSCs (e.g., flow cytometry,
western blotting).
2. Characterisation and purification of EVs, including MSC purification to extract EVs, EV
dimensions, EV biomarkers, imaging used to visualise EVs, and EV active component.
3. In vivo model, including method of EV delivery, type of in vivo model, how ten-
don/ligament injury was induced, animal age, animal weight, animal gender, total
number of animals used per experimental group, and follow-up time.
4. In vivo findings, including macroscopic appearance, imaging results, histopathologi-
cal results, biochemical findings, and biomechanical findings.
Quality assessment was carried out independently by MT and VL using the SYstematic
Review Center for Laboratory animal Experimentation (SYRCLE) tool [24]. The main
categories assessed were selection bias, performance bias, blinding bias, attrition bias, and
reporting bias. Discrepancies were consulted with WK.
This review was prospectively registered in the International Prospec-tive Register
of Systematic Reviews PROSPERO (https://www.crd.york.ac.uk/PROSPERO/display_
record.php?RecordID=257333, accessed on 25 September 2021).
3. Results
A total of 383 studies were identified from database searching. After de-duplication,
247 studies were identified for title and abstract screening, of which 17 full-text studies
were reviewed. Nine studies were eligible for data synthesis [25–33]. Searching references
of the included studies, as well as studies that cited any of the included studies, yielded
two more studies [34,35], giving a total of 11 studies for qualitative synthesis. All were
case–control studies. A PRISMA diagram is shown in Figure 1.
3.1. Characterisation of MSCs
The majority of studies used animal-derived MSCs rather than human-derived MSCs
(Table 1). Of the seven studies that used animal-derived MSCs (involving 310 subjects),
the most common MSC donor was Sprague–Dawley rats, with four studies involving
172 subjects utilising them [25,27,32,34]. One study involving 16 subjects used the Lewis
rat [29], and one study involving 32 subjects used NF-κB–luciferase reporter mice [26].
This was done to investigate how MSC-EVs could alter macrophage NF-κB inflammatory
signalling [26]. Of the four studies that used human-derived MSCs, involving 138 sub-
jects [30,31,33,35], two studies involving 93 subjects obtained MSCs from the umbilical
cord [30,33], one study involving 35 subjects from adipose tissue [35], and one study
involving 10 subjects from bone marrow cells [31].
Regarding the culture medium, alpha-modified minimum essential medium (α-MEM)
was most commonly employed, used in seven studies involving 325 subjects. Other
culture methods include Dulbecco’s Modified Eagle’s Medium (DMEM) utilised in two
studies involving 72 subjects [32,34], MesenCult™ Basal Medium utilised in one study
involving 16 subjects [29], and serum-free medium (OriCell) utilised in one study involving
35 subjects [35].
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The two most common methods for characterising MSCs were surface-maker expres-
sion using flow cytometry (used in seven studies with 310 subjects [25–29,32,34]), and
testing for the absence of haematopoietic surface markers CD34 and CD45 (used in five
studies involving 226 subjects [25,28,29,32,34]). Another, less common method was trilin-
eage differentiation into adipocytes, osteoblasts, and chondrocytes, seen in four studies
involving 140 subjects [27,29,32,34].
Table 1. Characterisation of MSCs.
Article Source Cell Origin Cell Tr atment MSC Verification
Shi et al. [25] Sprague–Dawleyrats
Bone marrow cells
from the femur and
tibia
Cultured in α-MEM containing 10%
FBS until third to fifth passage.
MSCs were then cultured in Mesen
Gro MSC medium.
Flow cytometry: CD44,











Cultured in 10% FBS, 100 unit/mL




Yu et al. [27] Sprague–Dawleyrats
Bone marrow cells
from the femur and
tibia
Cultured in α-MEM containing 10%
FBS, 100 U/mL penicillin and 100
mg/mL streptomycin until second







Shi et al. [28] C57BL/6 male mice Bone marrow cellsfrom the femur
Cultured in α-MEM supplemented
with 20% FBS, 1% penicillin, and
streptomycin until third to fifth
passage.
Flow cytometry: CD44,
CD90, Sca-1 +ve; CD34,
CD45 −ve
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Table 1. Cont.




from the femur and
tibia
Cultured in MesenCult Basal
Medium, supplemented with
penicillin/streptomycin
(100 U/mL–100µg/mL) and 10%





CD44, CD90 +ve; CD45,
CD34 −ve
Yao et al. [30] Human Umbilical cord Cultured in α-MEM mixed with 10%FBS until 3rd to 5th passage. Not done.
Chamberlain
et al. [31] Human Bone marrow cells
Cultured in α-MEM mixed with 10%
FBS, 1× nonessential amino acids,








from the femur and
tibia
Cultured in standard media
comprising DMEM supplemented







CD73, CD90, CD105 +ve;
CD34 −ve
Li et al. [33] Human Umbilical cord
Cultured α-MEM supplemented










Cultured in DMEM containing 10%
FBS, 100 U/mL penicillin and 100
mg/mL streptomycin until day 7.






CD90 +ve; CD3, CD34 −ve,
staining by Sirius red, Oil






Cultured in serum-free medium
(OriCell). The second and third
passages were used for ASCs-Exos
isolation.
Not done.
α-MEM = alpha-modified minimum essential medium; FBS = foetal bovine serum; DMEM = Dulbecco’s Modified Eagle Medium; NGL =
NF-κB-GFP-luciferase; MSCs = mesenchymal stem cells; ASCs = adipose-derived mesenchymal stem cells.
3.2. Characterisation of EVs
All studies isolated their EVs from MSCs using cell-culture media by differential
centrifugation and ultracentrifugation (Table 2). Shen et al. created two EV groups, one
isolated from MSCs that was primed with 100 ng/mL IFNγ at passages two to four (labelled
‘iEV’), and one isolated from MSCs without IFNγ pre-treatment [26]. This was done based
on previous literature suggesting that MSC-EVs primed by inflammatory mediators could
enhance their immunosuppressive functions [36]. Li et al. also created two EV groups,
one derived from hydroxycamptothecin-primed human umbilical cord MSCs, and one
from unprimed MSCs. The rationale was that hydroxycamptothecin elicits endoplasmic
reticulum (ER) stress in MSCs, leading to increased ER stress effector proteins in secreted
EVs, which increases the ability for EVs to prevent myofibroblast transformation and hence
tendon adhesion [33].
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Table 2. Characterisation of EVs.






Conditioned media concentrated by
several centrifugation and
ultracentrifugation, then passed
through a 0.22 µm filter.









by several centrifugation and
ultracentrifugation, then passed
through a 0.22 µm filter.
qNano Gold: Mode
diameter of iEVs and EVs
were 108 ± 2 nm and 113
± 3 nm, respectively.
CD9, CD63 TEM Notassessed
Yu et al.
[27]
Conditioned media concentrated by
several centrifugation and
ultracentrifugation.
NTA with ZetaView: 101.1



















Conditioned media concentrated by
several centrifugation and
ultracentrifugation.
AFM: 40–280 mm in













Conditioned media concentrated by
several ultracentrifugation steps.
NTA with ZetaView:











Conditioned media concentrated by
differential centrifugation and
ultracentrifugation steps.








Conditioned media concentrated by
differential centrifugation and
ultracentrifugation steps.
TEM: 30–150 nm CD9, CD63, andCD81 TEM
Not
assessed
Li et al. [33]
Conditioned media concentrated by
differential centrifugation and
ultracentrifugation steps.





Conditioned media concentrated by
differential centrifugation and
ultracentrifugation steps.
TEM: 40–200 nm CD63 and CD81 TEM Notassessed
Wang et al.
[35]
Conditioned media concentrated by
several centrifugation and
ultracentrifugation.





EV = extracellular vesicle; NTA = Nanoparticle tracking analysis; TEM = Transmission electron microscopy; ATM = Atomic force microscopy.
The most widespread method of visualising EVs was using transmission electron
microscopy (TEM) (used in nine studies involving 372 subjects [25–28,31–35]), and of those,
three studies involving 105 subjects used the method to also measure EV dimensions [32–34].
Other methods of visualising EVs included atomic force microscopy (ATM), used in one
study involving 16 subjects [29], and an 80kV electron microscope [30]. Additional methods
for visualising EVs include tunable resistive pulse sensing (TRPS) using Izon’s qNano
Gold in four studies involving 125 subjects [25,26,31,35], nanoparticle tracking analysis
(NTA) with ZetaView in three studies involving 202 studies [27,28,30], and AFM in one
study [29]. EVs were characterised by flow cytometry and western blotting, with CD9,
CD63, TSG-101 being the most common EV markers identified. Gissi et al. attributed
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the increased extracellular matrix–tendon remodelling to MMP14 and pro-collagen1A2,
which were identified in EVs by dot blot [29]. Yao et al. concluded that human umbilical
cord-derived MSCs release low levels of miR-21a-3p, which manipulates p65 activity to
inhibit tendon adhesion [30].
3.3. Animal Models
Rats were the most common animal model used, with ten studies involving 430 sub-
jects using them as recipients of EVs (Table 3). Amongst rat species, Sprague–Dawley rats
were the most frequently used [25,27,30,32–34]. The remaining study involving 18 subjects
used rabbits [34]. Across all eleven studies, 448 animal subjects (range: 10–90) were used
for in vivo analysis. Animal age and weight were reported in all but one study [25]. The
most common site used to induce tendon/ligament damage was the Achilles tendon,
whereby surgical removal was performed in six studies involving 251 subjects. Two studies
involving 100 subjects surgically removed part of the patella tendon [25,27], one study
involving 10 subjects transected the medial collateral ligament (MCL) at its midpoint [31],
and two studies involving 89 subjects created a rotator cuff tear model, by detaching the
supraspinatus at its insertion at the humerus [32,35]. Only one study involving 18 subjects
used a non-surgical technique, utilising type I collagenase solution to cause tendon dam-
age [34]. All studies injected EVs at the injury site, apart from Huang et al., who injected
exosomes into the tail vein of a rotator cuff tear murine model [32]. Follow-up time ranged
from 7 days to 18 weeks, with most studies sacrificing animals at different stages depending
on the outcome measure to be investigated. For example, Wang et al. randomly sacrificed
7 rabbits at 6 weeks for fatty infiltration assay, but sacrificed the remaining 21 rabbits at
18 weeks for histological and biomechanical evaluation [35].
All studies were designed in a case-control format. Three studies involving 116 subjects
divided their experimental subjects into two groups, a control and MSC-EV group [27,31,32].
The rest included multiple experimental groups, with one study involving 35 subjects
including a sham surgery group, whereby the tendon would be exposed but not surgically
manipulated [35]. One study investigating a dose-dependent relationship between EV
concentration and tendon repair further separated their EVs into high (8.4 × 1012 EVs) and
low concentrations (2.8 × 1012 EVs) [29]. One study utilised hydrogel to promote long-term
exosome retention and encourage sustained exosome release, and hence created a separate
group that only received hydrogel [28]. Shen et al. compared the efficacy of IFNγ-primed
MSC-EVs versus naïve MSC-EVs and hence had three experimental groups in total [26].
3.4. In Vivo Findings
Six studies involving 280 subjects performed macroscopic analysis [27,28,30,31,33,35],
but one only used it to look for fatty infiltration, confirming the establishment of a rotator
cuff tear model (Table 4) [35]. Yu et al. showed that the appearance of the injured tendon
better approximated normal tendon after exosome treatment [27]. Two studies involving
100 subjects observed reduced scar formation [28,31] and two studies involving 93 subjects
reported reduced tendon adhesion to peri-tendinous tissue [30,33]. Histological analysis
was performed by all studies. Five studies utilised scoring systems; Shi et al. utilised a
fibre alignment score as a proxy for tendon healing [25]. The other four studies involving
161 subjects used histological scores, which includes sub-scores such as fibre structure,
cellularity, vascularity, degree of adhesion [27,29,30,33]. Collagen deposition and alignment
were assessed by eight studies involving 345 subjects [25–28,30,31,34,35], all of which
reported more compact and regularly aligned collagen fibres in EV-treated tendons. One
study utilised angiography to show that exosomes promoted angiogenesis around the
injury site [32].
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Table 3. Characteristics of animal models.






Gender Follow-up Number per Experimental Group
Shi et al. [25]
10 µL of fibrin containing 25 µg
BMSC-EVs was applied around
the injury site.
Sprague–Dawley rats
Central 1/3 of patellar tendon
was removed from the distal
apex of the patella to the
insertion of the
tibial tuberosity.








(1) BMSC-EVs group (n = 16)
(2) Fibrin group (n = 16)
(3) Control group, left untreated
(n = 16)
Shen et al. [26]
ASC-EVs were loaded to the
surface of a collagen sheet, that
was cut into strips, each
containing 5–6 × 109 EVs.
Applied around the defect site.
NGL transgenic reporter mice.
Right Achilles tendon 2/3




32 3–4months 27 ± 5 g
Male and
female 7 days
(1) Collagen sheet loaded with EVs
from naïve ASCs (n = 11)
(2) Collagen sheet loaded with EVs
from IFNγ-primed ASCs (n = 10)
(3) Collagen sheet only (n = 11)
Yu et al. [27]
5 µL of BMSCs-exos (4 µg/µL)
was mixed with 1 µL thrombin
(500 IU/mL) and 4 µL
fibrinogen (50 mg/mL),
injected into the defect site.
Sprague–Dawley rats
Central 1/3 of the patellar
tendon (0.8 mm in width) was
removed from the distal apex
of the patella to the insertion
of the tibial tuberosity.











(1) Fibrin-exos (fibrinogen, thrombin,
and exosomes injected) (n = 26)
(2) Fibrin-vehicle (fibrinogen,
thrombin, and PBS injected) (n = 26)
Shi et al. [28]
Exosomes were mixed with
hydrogel before implantation
into the cut Achilles tendon.
C57BL/6 mice.
The Achilles tendon was cut
off above the calcaneus.
90 8 weeks 20–25 g Male 7 days
(1) Control group (n = 30)
(2) Hydrogel group (n = 30)
(3) Hydrogel + exosome group (n = 30)
Gissi et al. [29]
50µL of PBS was injected
locally with either EVL (2.8 ×
1012) or EVH (8.4 × 1012).
Lewis mice.
Bilateral Achilles tendon
defect 2 mm in diameter was
made in each animal.
16 Adult 180–200 g Male 30 days
(1) PBS alone (control group) (n = 4)
(2) rBMSCgroup: 4 × 106 cells (n = 4)
(3) EVL group: 2.8 × 1012 EVs (n = 4)
(4) EVH group: 8.4 × 1012 EVs. (n = 4)
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Table 3. Cont.






Gender Follow-up Number per Experimental Group
Yao et al. [30]
Injected subcutaneously
around injury site with
HUMSC-Exos (200 µg)
dissolved in PBS and an equal
volume of PBS (50 µL).
Sprague-Dawley rats.
The Achilles tendon was cut
in the middle.
60 Adult 200–250 g Male 3 weeks
(1) Sham group (n = 20)
(2) HUMSC-Exos group (n = 20)
(3) PBS group (n = 20)
Chamberlain
et al. [31]
Injected 1 × 109 exosomes to
MCL transection site.
Wistar rats
Bilateral MCL transection at
its midpoint.




precipitated in 200µL of PBS
was injected into the tail vein.
Sprague-Dawley rats.
2 mm of the distal tendon of
the supraspinatus was cut off.
54 4 weeks 70–100 g Male 4 weeks (1) BMSC-Exos group (n = 27)(2) PBS (control) (n = 27)
Li et al. [33]
HCPT-EVs were both
subcutaneously injected at the
injury site at a dose of 200µg.
33 Sprague-Dawley rats
The Achilles tendon was
transected in the middle and
repaired using the 6-0
polypropylene suture.
33 Adult 250–300 g Male 3 weeks
(1) PBS (n = 11)
(2) Unprimed EV injection (n = 11)
(3) HCPT-EV injection (n = 11)
Wang et al.
[34]
20 µL of exosomes
(486.3 µg/mL) was injected into
the Achilles tendon injury site
twice a week.
18 male Sprague-Dawley rats
Rats were injected with 30 µL
type I collagenase solution
(10 mg/mL) into both
Achilles tendons.
18 8 weeks 200–250 g Male 4 weeks
(1) PBS (control) (n = 6)
(2) Injury group with TSCs (n = 6)
(3) Injury group with exosomes (n = 6)
Wang et al.
[35]
1011 ASC-Exos suspended in 20
µL of saline were injected at the
injury site of the
supraspinatus muscle.
Rabbits: Bilateral rotator cuff
tear model.
The supraspinatus tendon
was detached at the insertion
on the humerus. The torn
tendon was wrapped with a
silicon Penrose drain to
prevent adhesion.
35 4 months 3.3 ±0.3 kg Male 18 weeks
(1) Repair + saline (n = 7)
(2) Repair + ASC-Exos (n = 7)
(3) Sham surgery (n = 14)
(4) Fatty infiltration assay (n = 7)
EVs = extracellular vesicles; MSC = mesenchymal stem cells; BMSC = bone marrow-derived multipotent mesenchymal stromal cells; rBMSCs = rat bone marrow-derived MSCs; ASCs = adipose-derived
mesenchymal stem cells; PBS = phosphate-buffered saline; HUMSC = human umbilical mesenchymal stem cells; NGL = NF-κB-GFP-luciferase; HCPT = hydroxycamptothecin.
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Table 4. In vivo Findings.
Article MacroscopicAppearance Imaging and Histology Biochemical Analysis Biomechanical Analysis
Shi et al.
[25] Not undertaken.
Regularly aligned and compact collagen
fibres.
Fibre alignment score of 2 (50% to 75%
parallel fibre alignment)
Increased tendon cell proliferation, especially
after treatment with BMSC-EVs at 20 µg/mL.
Elevated number of cells expressing CD163, IL-4,
and IL-10 in the BMSC-EVs group.
Reduced number of cells expressing IFNγ, IL-1B,
IL-6, and CCR7 in the BMSC-EVs group.
Increased expression of SCX, TNMD, COL1a1, and
COL3a1 in the BMSC-EVs group.
Increased gene expression of collagen type I in the
BMSC-EVs group.





Significant reductions of NF-κB activity in
iEV-treated tendons compared to untreated
tendons, but little reduction after EV
treatment.
Lower gap-rupture rate.
iEV-treated tendons exhibited more collagen
staining at the site of tendon injury than did
untreated and EV-treated tendons.
Expression levels of inflammatory genes Ifng,
Nos2, Tnf, Il6, Mmp1, Col1a1 and Col3a1 increased
after injury.
Treatment with iEV but not EVs significantly
reduced Il1b and Ifng expression.
Treatment with both iEVs and EVs significantly
attenuated the Mmp1 expression, increased Col2a1
and Sox9 expression.
iEV but not EV treatment further increased both






integration of the healing
tissue with the host





native tendon at week 4.
More deposition of extracellular matrix type I
collagen at week 2.
At week 4, cell density and alignment in the
defect region of the exosome-treated group
were much closer to the native tendon.
Lower histological score in the
exosome-treated group at week 4 (suggesting
better tendon regeneration).
The exosome-treated group showed much higher
expression of Col I and Tnmd.
The ratio of proliferating CD146+ TSPC to total
CD146+ cells was 1.73–fold higher in the
exosome-treated group 1–3 days post-injury, but
not afterwards.
Method: The tendon tissue was put on a
universal tensile testing machine (AGS-X,
SHIMADZU), cyclically elongated for 20 cycles,
and stress at failure was calculated as ultimate
load divided by cross sectional area.
Results: The stress at failure of the healing
tendons and modulus were 1.84–fold and
1.86–fold higher in the exosome-treated group
compared to the control.
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Table 4. Cont.
Article MacroscopicAppearance Imaging and Histology Biochemical Analysis Biomechanical Analysis
Shi et al.
[28]
Initially, there was less
scar hyperplasia in the
hydrogel + exosome
group than in the control
and hydrogel groups.
In the hydrogel+exosome group, a transition
structure similar to tendon–bone interface
was seen, chondrocyte numbers increased
and were tightly arranged, collagen tissues
were arranged orderly.
M2 macrophages (Arg1+) increased and M1
macrophages (iNOS+) decreased in the
hydrogel+exosome group.
The hydrogel+exosome group showed decreased
IL-1β and IL-6 and increased IL-10 and TGF-β1.
Reduced TUNEL-positive apoptotic cells,
increased CD146-positive stem cells in the
hydrogel+exosome group.
Increased gene expression level of collagen II in
hydrogel+exosome group.
Method: The tissue was loaded into a universal
testing machine, preloaded with small tension,
then stretched to failure at a constant speed.
Results: Maximum force, elastic modulus, and
strength in the hydrogel+exosome group were
higher than hydrogel and control groups, but no
significant difference with the normal group.




Lower overall histomorphometric score in
EVH group than rBMSC and EVL groups.
Only the cellularity sub-score in the EVH
group was higher than the control group.
Overall suggests a better restoration of
tendon architecture, optimal alignment of
tendon fibres and blood vessels in the
EVH group.
The EVH group had a more favourable collagen
ratio: higher collagen type I and lower collagen




The degree of adhesion
of tendon tissue with
HUMSC-Exos
application was lower





Hyperproliferative adhesion tissue, and
degree of inflammatory infiltration were
lower in the HUMSC-Exos group compared
to the PBS and sham groups.
The HUMSC-Exos group had the lowest
histological adhesion score.
The histological healing score was not
statistically different among the three groups.
The HUMSC-Exos group had the least
collagen deposition.
HUMSC-Exos significantly decreased COL III,
α-SMA, p-p65, and COX2 expression.
Method: Tendon tissue fixed to a biomechanical
analyser (Instron 8841 DynaMight axial servo
hydraulic test system), stretched at constant
speed until the tendon broke.
Results: No significant difference in maximum
tensile strength between the three groups.
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Table 4. Cont.
Article MacroscopicAppearance Imaging and Histology Biochemical Analysis Biomechanical Analysis
Huang
et al. [32] Not done.
Angiography showed that BMSC-Exos
promoted angiogenesis around the rotator
cuff endpoint.
BMSC-Exos promoted the expression of CD31 and
endomucin.
BMSC-Exos significantly reduced the serum levels
of TNF-α, IL-1β, IL-6, and IL-8.
BMSC-Exos promoted Col I and Col II expression,
expression of Sharpey’s fibres and proteoglycan at
the tendon-bone interface.
Method: Freshly excised tissue was immediately
placed in paraformaldehyde solution, then
loaded onto biomechanical tester, with a constant
displacement distance being applied until failure.
Results: BMSC-Exos increased the maximum







compared to the control.
Exosome treatment increased type I and type
III collagen production within the
granulation tissue.
Exosome treatment improved collagen
organisation.
IHC analysis CD68, CD163, CD31, and α-smooth
muscle actin levels, to identify M1 and M2
macrophages; no changes elicited in M1 and M2
macrophages.
Method: Mounted in the mechanical testing
machine, preconditioned with cyclic preloading,
then pulled to failure at constant strain rate, with
parameters recorded.
Results: Treatment with exosomes did not










Histological adhesion scores based on
histological findings. The results showed that
both unprimed EVs treatment and HCPT-EVs
treatment dramatically lowered the adhesion
grade of the tendon. Comparing the scores
achieved by HCPT-EVs with unprimed EVs
showed a tendency toward decreasing,
although it was not significant.
The histological healing score was
significantly lower in the group treated with
HCPT-EVs than with unprimed EVs.
HCPT-EVs more effectively decreased
myofibroblast activation induced by TGFβ after
tendon injury, as demonstrated by weaker WB
staining of both COL III and α-SMA in unprimed
EVs or HCPT-EVs.
qRT-PCR analysis suggested that unprimed EVs
and HCPT-EVs suppressed COL III and α-SMA at
the transcription level and displayed a larger
decreasing trend after HCPT-EVs administration
than with unprimed EVs.
Method: Both ends of the tissue are clamped in a
tensile testing system, and stretched at a constant
speed of 10mm/minute until rupture. The
maximum tensile force was recorded. Five
samples from each group were used for analysis.
Results: The maximal tensile strength of the
regenerated tendon remained the same among
the three groups.
Wang
et al. [34] Not done.
The arrangement of collagens in the
exosomes group was more uniform than that
of the injury group.
TSCs injection and exosomes injection significantly
decreased matrix metalloproteinases (MMP)-3
expression, increased expression of tissue inhibitor
of metalloproteinase-3 (TIMP-3) and Col-1a1
Method: The two bony ends of the tendon were
fixed on a custom-made testing jig with two
clamps. No further details are available.
Results: Ultimate stress and maximum loading
were significantly increased in the exosome
treated group compared with injury. No TSC vs
exosome comparison was made.
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Table 4. Cont.





rabbits with rotator cuff




rotator cuff tear model).
Few inflammatory cells were present in the
ASC-Exos group than in the saline group
Cellularity and vessel numbers at
tendon-bone interface of the ASC-Exos group
were significantly lower than those in the
saline group.
The fibrocartilage area in the ASC-Exos group
was significantly greater than in the saline
group.
More abundant collagen II and tenascin-C
appeared in the ASC-Exos group than in the
saline group.
Lower expression of CD31 in the ASC-Exos group
than the saline group, attributed to the maturation
of tiny capillaries into proper blood vessels.
Method: Tendons harvested and loaded into
clamping device. Specimens were preloaded to 5
N for 5 min, with 10 cycles of preconditioning (5
N to 30 N at a rate of 15 N/s). Then, each
specimen was loaded to failure using a
0.5-mm/min uniaxial tension. Ultimate load to
failure, stiffness, and stress were calculated
according to the load-elongation curve.
Results: Mean ultimate load to failure of the
ASC-Exos group (132.7 ± 10.3 N) significantly
greater than that in the saline group (96.0 ± 9.8
N) though lower than in the sham surgery group
(162.2 ± 12.1 N).
EVs = extracellular vesicles; iEV = IFNγ primed EVs; MSCs = mesenchymal stem cells; ASCs = adipose-derived mesenchymal stem cells; TSCs = tendon stem cells; TSPCs = tendon stem/progenitor cells; BMSC =
bone marrow-derived multipotent mesenchymal stromal cells; rBMSCs = rat bone marrow-derived MSCs; HUMSC = human umbilical mesenchymal stem cells; IHC = immunohistochemistry.
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All studies performed biochemical analysis. Four studies involving 227 subjects
explicitly mentioned that EVs reduced the expression of pro-inflammatory cytokines such
as IL-1β and IL-6, and increased expression of anti-inflammatory cytokines such as IL-
10 and TGF-β1 [25,28,32,35]. Shen et al. demonstrated decreased gene expression and
protein expression in the tendon not performed. Three studies involving 154 subjects
directly tested the impact of EVs on macrophage polarisation [28,31,32]. Huang et al.
showed that exosomes decreased CD86, an M1 macrophage surface marker [32], whilst Shi
et al. demonstrated that exosomes decreased iNOS+ M1 macrophages and increased Arg1+
M2 macrophages [28], despite the former being done in vitro. However, Chamberlain
et al. reported that exosome treatment had no significant effect on M1 or M2 macrophage
number, whilst EV-educated macrophages (made by exposing CD14+ macrophages to
MSC-EVs) decreased endogenous M1/M2 macrophage ratio [31]. Virtually all studies
reported increased expression of genes related to collagen and tendon matrix formation,
such as COL1a1, COL2a1, COL3a1, SCX, Sox9. Gissi et al. also reported a more favourable
collagen ratio after EV treatment, i.e., increased collagen type I and decreased collagen
type III expression [29].
Eight studies performed biomechanical analysis. In a bilateral rotator cuff tear model,
Wang et al. found that the mean ultimate load to failure in the MSC-EV treated group
was significantly greater (132.7 N versus 96 N) than in the control group [35]. In a murine
patellar tendon injury model, Yu et al. noticed that stress at the failure of the regenerated
tendons and Young’s modulus were 1.84-fold and 1.86-fold higher in the MSC-EV treated
group than controls [27]. Most other studies reported that EV treatment increased the
maximum stiffness, breaking load, and tensile strength of regenerated tendons; however,
three studies reported no significant difference in biomechanical properties between EV-
treated and control groups [30,31,33].
3.5. Risk of Bias
The SYRCLE risk of bias tool for animal studies was used, containing 15 different
parameters [24]. A summary of this is provided in Figure 2. Ten studies had a low level
of concern overall, but one study had some concern about the risk of bias [32]. The
main contributors to bias were blinding and detection bias. There was little selection and
reporting bias. Overall, the studies included in this review are of high quality with a low
risk of bias.
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4.1. S Isolation, ifferentiation, and ulture edia
urrent protocols for S isolation fro bone arro rely on density gradient cen-
trifugation ( C) or size-exclusion chro atography (SEC) [39–41]. Studies have de on-
strated that EV isolated fro ste cell culture by ultrafiltration follo ed by SEC results
in a higher yield while preserving EV biophysical and functional properties [42]. All the
included studies in this review only used several ultracentrifugation steps without SEC.
Obtaining high yields of MSCs is crucial for their clinical application. Improvements on the
current isolation protocol, e.g., the isolation of MSCs using a Good Manufacturing Practice
(GMP)–compatible fabric filter system device resulted in a higher yield of colony–forming
units fibroblasts (CFU-F), producing substantially more MSCs with a similar subpopulation
composition and functional characteristics as MSCs isolated by DGC [43].
Culturing autologous MSCs in different media and conditions has been shown to
affect growth characteristics, surface marker distribution and chondrogenic differentia-
tion [44]. The media used was DMEM or αMEM with varied concentrations of foetal
calf serum +/− additives, e.g., PDGF, FGF-2, and ascorbic acid. This study found that
chondrogenic differentiation was superior in a medium composed of DMEM with low
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glucose, 10% foetal calf serum, and 1% penicillin/streptomycin (referred to as medium
A) [44]. Sotiropoulou et al. showed that expansion media, growth factors, plating density
and flask manufacturer have an impact on MSC characteristics [45]. Some studies have
demonstrated inferior chondrogenic differentiation results of MSCs expanded in a control
medium when compared to embryonic stem cell medium [44,46]. In the absence of a
standardised culture protocol designed to maximise the chondrogenic differentiation of
MSCs, there will be continued variation between studies. Included studies utilised α-MEM,
DMEM, serum-free OriCell, and MesenCultTM; the type chosen did not preclude MSC’s
ability to undergo trilineage differentiation and express important cell surface markers
such as CD44+ and CD90+. Nevertheless, only MSCs that were cultured in DMEM were
CD3− [34], and MSCs cultured in MesenCultTM Basal Medium were CD29+ [31]. α-MEM
is one of the most commonly used media, which contains higher concentration of essential
nutrients than its predecessor, basal medium eagle (BME). Sotiropoulou et al. reported that
culture media based on α-MEM are more suitable for the expansion and proliferation of
multipotent MSCs [45]. Only Chamberlain et al. added l-glutamine to the media [31] to
encourage MSC growth. Nevertheless, Sotiropolou et al. suggested that Glutamax better
supports MSC growth. Reasons were two-fold: (1) the presence of dipeptide l-alanyl-l-
glutamine in Glutamax; (2) metabolism of glutamine leads to ammonia, which restricts
MSC growth [47].
A number of studies compared the differentiation ability between MSCs derived from
different species and different sources. Scuteri et al. found that rat MSCs had a greater
chondrogenic and osteogenic differentiation potential than human MSCs, whereas human
MSCs had a greater adipogenic differential potential [48]. Scuteri et al. also noted variation
in differentiation time among human MSCs [48]. Martínez-Lorenzo et al. showed that
rabbit and sheep MSCs were able to differentiate into chondrocytic lineages more easily
than human MSCs [49]. Human MSCs from different sources display certain differences
despite meeting the minimal criteria of MSC characterization [50]. All seven of the included
studies that utilised animal-derived MSCs were able to undergo trilineage differentiation
into adipocytes, osteoblasts, and chondrocytes. However, the four studies that used human
MSCs did not report results of MSC differentiation, perhaps hinting reporting bias if their
MSCs performed poorly regarding differentiation [30,31,33,35].
Studies also attempted to identify markers associated with better MSC properties.
Nagano et al. demonstrated that human umbilical cord MSCs with a high ALDH activity
proliferated more than those with low ALDH activity [51]. Coipeau et al. suggested that
age and sex of the donors influence the differentiation process and found that trabecular
bone MSCs from elderly patients are not a good starting material for cell therapy usage
for bone repair and regeneration, unless cultured in the presence of FGF-2 [52]. This
suggests a possible role for allogenic MSC-EVs. Seven included studies added penicillin
and streptomycin to their culture medium [26–29,32–34] to avoid bacterial contamination.
However, in vitro studies have shown that antibiotics can modify gene expression via
drug-dependent gene regulatory elements [53]. Furthermore, Ryu et al. directly identified
a group of differentially expressed genes in HepG2 cells, that had significantly enhanced
expression in response to penicillin/streptomycin [54]. This suggests that data from studies
that utilise antibiotics in cell culture should be examined with caution.
All included studies supplemented their culture with foetal bovine serum (FBS), apart
from Wang et al., who cultured MSCs in a serum-free medium (OriCell) [35]. FBS contains
growth factors and macromolecular components essential for MSC growth. Nevertheless,
evidence suggests that it may be time to step away from FBS, not only due to issues such as
xenoimmunisation and contamination from viral or prion particles [55], but also because
of proven benefits from other serum supplements. Bovine serum albumin with insulin-
transferrin-sodium selenite better augmented protein expression levels in bovine embryos
than FBS [56]. GMP-compliant serum-free or xeno-free media are potential alternatives.
Adipose stem cells (ASCs) expanded in xeno-free media with significant higher doubling
rates than in FBS (p < 0.001) [57]. No included studies used human serum, which could
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create an environment more akin to that of humans. Shahdadfar et al. showed that
autologous human serum provides ASCs with a more rapid expansion and better genomic
stability than FBS [58].
4.2. EV Isolation and Administration
The choice of EV isolation procedure significantly impacts the EV yield from serum.
Brennan et al. highlighted challenges and limitations in isolating EVs from small volumes
of bio-banked serum [59]. The abundance of the EV marker CD63, detected by western blot,
correlated positively with the amount of protein in the sample and not the nanoparticle
tracking analysis (NTA) particle counts. Flow cytometry detection of CD63 is an alternative
approach to confirm EVs. It is likely that NTA overestimates the amount of EVs due to
the presence of protein aggregates and lipoproteins, which are often present in EV isolate
due to shared physical properties [60]. This highlights a limitation in using particles/ug to
determine EVs/ug when dealing with human serum. Resolution and accuracy are low for
particles with diameters <250 nm as multi-Gaussian fittings are often not obvious, meaning
that the size range of NTA is limited [61]. Eight of the included studies used CD63 as an EV
marker, with only Yu et al., Shi et al., and Gissi et al. opting not to use this [27–29]. Three
studies in this review [27,28,30] used NTA; hence, the EV yield could be lower than other
included studies. Strategies are being developed to obtain highly pure EVs from plasma
and serum without lipoprotein or soluble protein contamination e.g., using a combination
of differential ultracentrifugation and size exclusion chromatographyin tandem [62].
Different lipoproteins co-purified with EVs might promote pro or anti-inflammatory
responses. OA chondrocytes express receptors for oxidised low-density lipoprotein, which
promotes pro-inflammatory macrophage differentiation, and is implicated in OA dis-
ease progression [63]. Conversely, high density lipoproteins can bind pro-inflammatory
miRNAs [64]. Although there have not been studies demonstrating the implications of
co-isolated lipoproteins on tendon and ligament healing, further work must be done
to characterise any associated effects on ligament healing. This is particularly relevant,
as many of the included studies did not characterise the active EV component. Only
two studies identified their active components as Pro-collagen1A2 and MMP-14 [29] and
MicroRNA-21-3p [30], respectively.
The preferred application of exosomes was an intra-articular injection in aqueous
solution i.e., PBS or saline [29,30,32,35] (please refer to Table 3, method of delivery). Two
studies used fibrin gel [25,27], one an alternative hydrogel [28] and another a collagen gel as
their delivery vehicle [26]. Fibrin gel is a biologically derived and FDA-approved hydrogel,
favourable for cell adhesion and infiltration [65]. Yu et al. utilized fibrin gel as the carrier
of bone marrow-derived stem cell exosomes (BMSCs-exos), which was well retained in the
defect area, released into tissue, and internalized by local CD146+ TSPCs [27]. They used
lower doses of exosomes than previous studies based on a rat model [66] and attributed
their positive results to the fibrin gel’s controlled-release of EVs to the target site, so that
the concentration of exosomes in the injury area was likely to be higher than those applied
systematically.
Whilst all studies directly injected EVs intra-articularly, the dose delivered varied and
is not always reported. Chamberlain et al.’s Achilles’ tendon injury model used 1 × 106
EVs in their study, which is much lower than that used by Gissi et al. [29,31]. Gissi et al.’s
rat Achilles tendon injury model study data suggest that EV treatment accelerates the
progression of healing in the remodelling stage of tendon repair in a dose-dependent
manner [29]. Higher concentrations of MSC-EVs (8.4 × 1012 EVs in 50 µL PBS) performed
better than lower concentrations (2.8 × 1012 EVs in 50 µL PBS) and MSCs alone. Shi et al.
did not provide a concentration but did provide a weight of 25 µg BMSC-EVs [25], which
could contain variable amounts of lipoproteins contributing to the mass. Determining the
optimum dose of EVs is difficult since different animal models and different injury sites
were used; this should be a topic for further study.
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4.3. Modifying EVs to Enhance their Biological Function
There are many strategies that can modify bioactive molecules to enhance their treat-
ment effectiveness, such as the active loading of EVs with short interfering RNAs (siRNAs)
via electroporation [67] and the genetic modification of human adipose-derived stem cells
(hASCs) to load miR-375 into hASC-derived exosomes to improve osteogenic differentia-
tion [68]. Huang et al. pre-treated MSCs with atorvastatin to increase their cardioprotective
function. This resulted in lower cardiomyocyte apoptosis and greater angiogenesis in
rat models of acute myocardial infarction [32]. Wang et al. performed cyclic stretch on
human periodontal ligament cells resulting in the secretion of exosomes that were better at
inhibiting proinflammatory IL-1β secretion from macrophages [34]. Li et al. pre-treated
human umbilical MSCs with hydroxycamptothecin, resulting in a greater suppression on
fibroblast proliferation and a better extrinsic fibrotic tendon repair, paving the way for im-
proved natural intrinsic tenocyte regeneration [33]. Studies suggest that pro-inflammatory
stimuli increase the immunosuppressive functions of MSC-EVs [69,70]. Shen et al. found
that IFNγ-primed MSCs produced EVs that can better reduce NF-κB activity and the
subsequent expression of pro-inflammatory mediators in injured tenocytes, and promote
macrophage differentiation into the anti-inflammatory M2 phenotype [26]. A similar effect
has also been reported in in vivo models of cartilage injury, with IFNγ-stimulated MSCs
enhancing chondrogenesis [71].
Role of MMP-14 and miR-21 in Tendon/Ligament Repair
The tendon regeneration capabilities of MSC-EVs have been ascribed to various active
components that they secrete. Gissi et al. partly attributed the increased tendon healing
in a rat Achilles tendon injury model to pro-collagen1A2 and MMP-14 expression in EVs
derived from rat bone marrow MSCs (rBMSCs-EVs) [29]. Gulotta et al. suggested that
MMP-14, which plays a role in tendon-bone insertion site formation during embryoge-
nesis, is responsible for increased biomechanical strength and fibrocartilage presence at
tendon–bone insertion sites [72]. In a complete flexor tendon laceration rat model, Oshiro
et al. noted that MMP-14 levels steadily increased in the intermediate to later stages of
tendon healing [73]. This suggests that in addition to its key role during embryogene-
sis [74], MMP-14 is necessary for the remodelling phase of tendon healing. The exact
mechanism is unknown; however, some studies suggest that MMP-14 is a key player in
the cell surface activation of MMP-2 [75], MMP-9, and MMP-13 [73], resulting in tissue
remodelling. Mechanistically, tendon repair via MSC-derived MMP-14 could happen by
increased degradation of weaker fibrotic tissue, as suggested by increased cardiac fibroblast
degradation after MSC treatment in a rat model of post-ischaemic heart failure [76]. Fur-
thermore, studies have shown that MMP-14 is a collagenolytic enzyme that plays a crucial
role in collagen homeostasis, whose inhibition in a mice MMP-14 knockout model led to a
fibrosis-like phenotype [77]. MMP-14 could also trigger COX-2 expression, as shown in a
study using U87 glioma cells [78]. COX-2 inhibition has been shown to be detrimental to
healing at the tendon-to-bone interface in a study where the tendon healing failure rate
was significantly higher in rats treated by NSAIDs than in the control group [79]. Thus, it is
possible that MMP-14 re-establishes a niche that is similar to native tissue, and conducive
to tendon healing.
The beneficial effects of MSC-EVs have also been ascribed to the decreased secre-
tion of mediators. miR-21 is a known regulator of tissue fibrosis. A recent study used
high-throughput miRNA sequencing to show that miR-21a-5p was highly enriched in
macrophage exosomes and promoted tendon adhesion via Smad7 expression [80]. With
this theoretical basis, Yao et al. sequenced human umbilical MSCs (HUMSCs) and their
derived exosomes and found that miR-21a-3p was among the most highly expressed [30].
In vivo studies showed that HUMSCs-derived exosomes had a lower expression of miR-
21a-3p than HUMSCs, leading to reduced TGF-β1-induced fibroblast proliferation. Ex-
cessive extracellular matrix deposition, as indicated by increased collagen III and α-SMA
expression, are pathognomonic for fibrotic disease. The lower expression of miR-21a-3p
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in HUMSCs-derived exosomes resulted in significantly lower collagen III and α-SMA
expression, consistent with the conclusion that a low abundance of miR-21 activity leads to
decreased fibrosis and tendon adhesion [30].
4.4. EV Educated Macrophages
There is evidence that a main path by which MSC-EVs contribute to tendon and
ligament repair is through effects on other cells, with macrophages being important targets.
These macrophages are known as EV-educated macrophages (EEVs). It is well known that
macrophages play a key role in all stages of tissue repair. Regarding tendon healing, biome-
chanical testing demonstrated that macrophage metalloelastase-deficient mice had a lower
ultimate force and stiffness and a decreased level of type I pro-collagen mRNA compared to
wild-type mice [81]. In vivo macrophage depletion using clodronate liposomes during the
early healing process (day 5) limited granulation tissue formation and comprised final liga-
ment strength, even though macrophage levels returned to normal after day five [82]. de
la Durantaye et al. injected mice four hours prior to tenotomy with clodronate liposomes,
with daily injections until four days post-surgery, and found a decreased extracellular
matrix formation and cell proliferation compared to PBS-treated mice [83]. However, it
was reported that clodronate-treated mice had greater Young’s modulus and maximal
stress than PBS-treated mice. The superior ultimate tensile stress in clodronate-treated mice
appears to contradict the findings of Schlundt et al. [84]. Yet, this could be explained by the
fact that clodronate treatment was limited to four days post-surgery, thus mainly affecting
M1 macrophage levels, which is the first subset to invade tissues. After an injury, an acute
inflammatory reaction is usually accompanied by extensive M1 macrophage infiltration,
which secretes pro-inflammatory mediators (TNF-α, IL-6, IL-1β) to increase vessel wall
permeability, recruit leukocytes and fibroblasts [85]. M1 macrophages have also been
reported to inhibit chondrogenesis, exacerbate experimental osteoarthritis [86] and inhibit
the tenogenic differentiation of tendon-derived stem cells [87]. Afterwards, macrophages
are polarised into the M2 phenotype which secrete anti-inflammatory cytokines (TGF-β,
IL-10) for inflammation resolution and repair. However, excessive M1 macrophage activity
encourages excessive fibroblast activity, leading to scar tissue formation. This hampers
tissue remodelling at tendon–bone interfaces and fibrocartilage repair, whilst increasing
fibrosis and tendon adhesion [88]. This suggests that excessive M1 macrophage activity is
likely responsible for the inferior mechanical properties of Achilles tendons in the study by
de la Durantaye et al. [83].
Shi et al. used an Achilles tendon murine model and showed that seven days af-
ter tenotomy, bone marrow MSC-derived exosomes (BMSC-exos) increased Arg1+ M2
macrophages and decreased iNOS+ M1 macrophages [28]. In an in vitro study, Cham-
berlain et al. generated EEVs, which were M2-like macrophages, by exposing CD14+
macrophages to EVs [31]. The functional benefits conferred by an increased M2:M1
macrophage ratio was shown macroscopically by reduced scar hyperplasia in the BMSC-
exos treated group and histologically by an increased Safranin O-positive area, suggesting
increased regeneration at the tendon–bone interface. Finally, the BMSC-exos treated group
enjoyed increased maximum force and Young’s modulus compared to controls, with
no significant difference with the normal group [28]. Nevertheless, TGF-β secreted by
M2 macrophages can promote fibrosis and pathological scarring. The persistence of M2
macrophages at the injury site can result in rebound localised fibrosis and the incomplete
resolution of inflammation after a tendon injury, as shown by decreased lipoxin A4 produc-
tion [89]. Li et al. showed that hydroxycamptothecin (HCPT)-primed EVs or unprimed EVs
reduced TGF-β1 mediated cell proliferation compared to the control group, with HCPT-
EVs almost abolishing TGF-β1 mediated fibroblast proliferation [33]. This was shown
histologically by reduced collagen III and α-SMA expression. Furthermore, MSC-EV mod-
ulation of macrophage polarisation can be context dependent. Systemic administration of
IL-1β-primed MSCs increased macrophage M2 polarisation and increased the survival rate
of murine sepsis only in the presence of miR-146a. Exosome-mediated transfer of miR-146a
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was shown to be necessary for the immunomodulatory response of MSCs [36]. Proteomics
has also identified differences in the fibrotic potential of EVs harvested from different
tissue, with tendon fibroblast-derived EVs containing a much higher amount of TGFβ1
than EVs from myoblasts and muscle fibroblasts. Nevertheless, Xu et al. reported that
TGFβ is necessary for tendon-derived stem cell (TSC) exosomes to induce MSCs to secrete
type I collagen [90]; this was confirmed by a rat Achilles collagenase-indued tendinopathy
model, which reported a more ordered collagen fibre arrangement and increased ultimate
stress and maximum loading [34].
4.5. Animal Models of Tendon/Ligament Injury
Animal models are crucial for modern biomedical research. They are used for diverse
objectives, from testing novel pharmaceutical components to exploring new pathophysio-
logical pathways, and are used when it is unethical or inconvenient to study on humans.
However, due to the ‘unity in diversity’ concept, suggesting homology due to common
evolutionary origins predicts functional similarities [91], there is a lack of guidelines and
protocols for choosing the best animal model for a particular clinical context. Even hu-
manised mice, which carry human genes or tissues, still cannot perfectly model complex
human diseases like sepsis [92]. Given the enormous burden tendon and ligament injury
places on society, evidence-based selection of fit-for-purpose animal models is essential.
Soslowsky et al. developed a 34-item checklist to assess the suitability of various
animals for modelling human rotator cuff tendinopathy, deeming the rat the only appropri-
ate model [93]. When running, the rat’s acromion creates an enclosed arch under which
the supraspinatus tendon passes, similar to the human when lifting objects overhead [94].
However, the rat shoulder anatomy is slightly different; instead of the acromion, cora-
coacromial ligament and coracoid forming the arch over the supraspinatus tendon, the
acromion, acromioclavicular ligament, and coracoid does so [95]. Furthermore, the use
of its four limbs for locomotion makes its shoulders ‘weight bearing’, unlike the human
shoulder. Nevertheless, human shoulders do bear a significant amount of stress during
normal everyday activities [96]. Shoulder function in rat models can be measured by
looking at ambulatory parameters. Stride length, defined as paw strike distance, is a proxy
for the rat’s capacity for forward flexion and motion. In a cohort study, stride length was
decreased after a multiple rotator cuff tendon detachment up to 56 days post-injury [97].
Yet, single rotator cuff tear models showed no change in stride length [98]. This suggests
that the extent of rotator cuff damage correlates with the extent of functional loss, which
is similar to that seen in humans, whereby those with a massive chronic rotator cuff tear
pattern experience a greater loss of active shoulder range of motion [99]. Thus, stride
length can be used as a valid modality to estimate the functional impact of rotator cuff
pathologies.
The lack of post-operative re-tears in rat models [100] makes it appropriate to investi-
gate biologically-based regenerative strategies for tendon/ligament repair and biomechani-
cal strengthening of the entheses. Tendons coated with growth factors such as GDF-5 [101]
and CDMP-2 [102] have shown more organized healing and superior biomechanical prop-
erties than untreated tendons, the results of which are more conspicuous in rat models
due to an intact tendon–bone healing surface. Rat models have also been used for studies
focusing on the biological repair of joints, rather than the anatomical repair, such as the
use of reinforcement scaffolds like electrospun chitosan-coated polycaprolactone (CS-g-
PCL) [103], or the reconstruction of large rotator cuff tears with acellular dermal matrix
grafts [104].
Wang et al. chose to use rabbits in their rotator cuff model [35]. Although mature, the
rabbits used were young, and rotator cuff tendinopathy usually occurs in the elderly. Both
Wang et al. and Huang et al. created rotator cuff models via acute injury by detaching
the supraspinatus tendon at the insertion on the humerus. The torn tendon was then
wrapped around a silicon Penrose drain to prevent adhesion [32,35]. Furthermore, the
anatomy of larger animals such as rabbits, sheep, and dogs, are not the same as humans.
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Sheep have no clavicle, a poorly developed acromion, and no acromioclavicular arch [105].
Nevertheless, sheep are often selected due to the similarity of their infraspinatus tendon
with humans’ supraspinatus tendon, in terms of microstructure, size, and shape [106], and
also because they become incapacitated if their supraspinatus is damaged [94]. The soft
tissue environment also differs, with rotator cuff tendons being extra-articular [105]. This
means that all repairs detach to a certain extent, with the intervening gap packed with
fibrous scar tissue, which does not represent direct tendon–bone healing in humans. Also,
a significant portion of the underlying joint capsule in large animals must be excised to
model an intra-articular injury [107].
Large animals, with more similar tendon dimensions and biomechanics [108], are
suitable for studies focusing on mechanical repair, comparing surgical repair techniques
such as single-row Mason–Allen stitch and double-row medial horizontal mattress stitch at
time zero [109,110], and after tendon healing [111]. The large size, the reduced ability for
suture retention due to a well-aligned tendon structure, and the occurrence of re-tears in a
proportion of subjects, even when post-operative activity is limited by attaching a 6-inch
softball under the foot of the operated limb [112], make it more suitable for evaluating
repair strategies focusing on mechanical stability and efficacy. However, like the rabbit
model used by Wang et al. [35], tendons are usually acutely severed and healthy, limiting
their efficacy when studying a natural degenerative process or chronically injured and
diseased human tendons.
Nevertheless, large animals have also been used to model chronic rotator cuff tears.
Coleman et al. reported that there is a significant increase in lipid levels in ovine rotator cuff
muscles six weeks after a rotator cuff injury, leading to muscle atrophy and stiffening [113].
After tenotomy, significantly increased Myf-5 and PPARγ expression were seen [114]; these
are two fat infiltration–related transcription factors found in atrophic ovine rotator cuff
myocytes. This makes ovine models well suited to study the management of human
rotator cuff tendinopathies with concomitant muscle pathology, since human rotator cuff
pathology is also associated with fatty infiltration and progressive degenerative changes
in rotator cuff muscles [115]. Coleman et al. suggested a ‘point of no return’ in rotator
cuff pathologies, after which the elasticity of the muscle–tendon unit can not return to
normal [113], hence frustrating any successful surgical or biological intervention. This
has led some to propose that surgical management for an injured rotator cuff should be
done before fatty infiltration becomes irreversible [116]. Furthermore, GFP labelling of
ovine bone marrow-derived MSCs (BMSCs) confirmed the plasticity of ovine MSCs, with a
transdifferentiation potential parallel to human BMSCs [117], suggesting the suitability for
sheep to act as pre-clinical models for cell replacement therapy research.
In addition to rotator cuff tendons, the patella tendon is of particular interest to
researchers, not only because it regularly experiences high loads, but also because it is
often used in anterior cruciate ligament (ACL) grafts. Shi et al. and Yu et al. utilised a
similar technique to tendon harvesting for ACL reconstruction, by creating a ‘window
defect’ model whereby the central third of the patellar tendon was removed from the distal
apex of the patella to the insertion of the tibial tuberosity [25,27].
Achilles tendon rupture is a frequent pathology in musculoskeletal clinics. Rats are
commonly used to model Achilles tendinopathy [26,28–30,33,34]. Most models are created
by transecting the tendon at the midpoint between the calcaneal insertion and musculo-
tendinous junction; however, Wang et al. used a collagenase-induced Achilles tendinopathy
model [34]. Recent novel approaches involve repeated Substance P injections together with
Achilles tendon overuse [118], enforced downhill running in a bipedal position [119], and
passive ankle exercise that simulated repetitive calf muscle contraction using an electrical
stimulator [120]. The equine superficial digital flexor tendon (SDFT) is often used to mimic
the human Achilles tendon, since they play similar roles during locomotion and are one of
the most commonly injured tendons in both species [121]. The SDFT is a weight-bearing
tendon, supports the metacarpophalangeal joint, and stores elastic energy during the stance
and releases it during the swing phase, allowing efficient movement in this athletic species,
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much like the Achilles tendon [122]. Moreover, with its relatively long life-span, equine
ageing best mirrors that of humans, and is good for studying ageing-induced tendon
degeneration. The frequent incidence of equine SDFT injury, with a 23% prevalence [123],
contributed to a ‘One Health One Medicine’ notion, suggesting that diseases in humans and
animals (especially mammals) are pathophysiologically alike and require similar manage-
ment plans [124]. Hurtig et al. suggested that in order to achieve a timely transition from
lab experiments to clinical use, it is best to initially utilise small lab animals, followed by
pilot studies on large animals, given that they have closer immunophysiological properties
to humans and are large enough for gait analysis and arthroscopic interventions [125].
It is accepted that no one animal model of tendon or ligament injury can perfectly
replicate human pathology. Oreff et al. calculated the Mahalanobis distances, a non-
dimensional measure of dissimilarity, of four model species to humans: mouse, rat, horse,
and sheep, and found that the species that best matched humans depended on which
functional group of genes were analysed [126]. Horses had the shortest Mahalanobis
distance to humans in terms of matrix remodelling proteinases, suggesting that horses are
most suitable for assessing ECM production and tendon healing. However, rat tenocytes
best resembled humans in terms of inflammatory mediators; furthermore, under healthy
conditions, rat tenocytes had the shortest Mahalanobis distance with regards to overall
gene expression [126], bringing into question Hurtig et al.’s proposition that large animals
have more similar properties to humans.
4.6. In Vivo Findings
No standardised histological or immunohistochemical tests were used across the
studies. Gissi et al. utilised a semi-quantitative histomorphometric scoring system [29]
that was modified from that proposed by Soslowsky et al., Svensson et al., and Cook
et al. [93,127,128]. This considered four parameters, namely cartilage formation, vascularity,
cellularity, and fibre structure. Yu et al. defined their own unique histological scoring
system with six parameters [27]. Both Yao et al. and Li et al. utilised the same histological
adhesion scoring system and histological healing scoring system; the former took into
account the percentage of adhesion area on the tendon surface, and the latter was based
on whether or not the collagen fibres looked smooth and regular [30,33]. Although many
histological scoring systems overlap in the parameters they look for, they nevertheless
present difficulty in pooling data, precluding any meta-analysis.
The organization of fibrous connective tissue within the defect site was evaluated using
a parallel fibre alignment scoring method [129]. While the histological grading methods
have been proven in vitro to be hallmarks of better healing, there are no studies directly
linking histological evidence of healing to mechanical strength. Yao et al. showed that
the exosome treated group had significantly decreased COL III, α-SMA, p-p65, and COX2
expression; however, these favourable immunohistochemical tests did not translate into
improved maximal tensile strength [30]. Similarly, Chamberlain et al. showed that exosome
treatment increased type I and type III collagen production within the granulation tissue;
however, it did not significantly improve mechanical function [31]. Li et al. demonstrated
that both unprimed EVs treatment and HCPT-EVs treatment dramatically lowered the
adhesion grade of the tendon; however, this did not increase the maximal tensile strength
of the regenerated tendon [33].
Biomechanical properties are the ultimate index for evaluating tendon–bone healing.
Although the animal models varied by species, joint and time post-EV delivery, when the
tendons were harvested for biomechanical testing, the methods used were very similar
across all studies (Table 4). All loaded tendons into universal testing machines and stretched
them to failure at a constant speed. Wang et al. [35] removed sutures prior to biomechanical
testing, allowing for the accurate testing of the repaired tendon segment. Challenges exist
with biomechanical testing of tendons. Many lab animals are quadrupeds and subject their
tendons to different magnitudes of load than their human counterparts, making it difficult
to replicate the pathology seen clinically. For all included studies, mechanical properties
Cells 2021, 10, 2553 23 of 30
were assessed in vitro after tendon dissection and removal of surrounding tissue. Ex vivo
testing of viable tendon samples provides information concerning the initial cellular and
matrix response to loading but still cannot take into account in vivo healing. The in vitro
testing methods discussed thus far can provide very controlled loading conditions, but
cannot mirror the complexity of the native tissue environment. In vivo, so-called animal
overuse models, overcome this by enabling the consideration of cellular responses within
the native tissue environment. However, the degree of reproducibility of loading can be
harder to control [130].
In vitro limitations include considerable issues associated with the gripping of the
two tendon ends, which precludes the testing of the tendon-to-bone attachment. Testing
the strength of the tendon-to-bone attachment is of considerable clinical value as rotator
cuff re-tears usually develop at the junction between the tendon and the bone [131,132].
Although there are limitations with the biomechanical models used, the data reviewed
is useful and all included studies faced the same limitations, making results comparable,
with a trend towards improved maximum force, elastic modulus, and strength in EV
treated groups.
Recommendations for future work would be the ex vivo testing of biomechanics using
novel 3D-printed fixtures that exactly match the anatomies of the humerus and calcaneus to
mechanically test supraspinatus tendon and Achilles tendon, respectively. Kurtaliaj et al.’s
new approach eliminated artifactual gripping failures (e.g., growth plate failure rather
than in the tendon), decreased overall testing time, and increased reproducibility [132].
Furthermore, it is challenging to generate models which mimic the cumulative damage seen
in age or overuse related tendinopathy. The mechanically and chemically induced models
used in these studies better model acute injuries. A representative pathophysiological
tendon model can be established by combining mild overstimulation for a longer period of
time (e.g., three weeks), mimicking the chronic situation, and acute extreme overloading
and/or scratch, representing the acute injury [133].
Three studies reported no significant difference in biomechanical properties between
EV-treated and control groups [30,31,33]. Yao et al. did not find a difference in terms of
biomechanical strength in the exosome-treated group [30]. The maximum tensile strength
was evaluated at three weeks following exosome treatment and primary repair with a 6-0
polypropylene suture. Li et al. also repaired the Achilles tendon using the 6-0 polypropy-
lene suture and harvested it after three weeks [33]. Chamberlain et al. utilised a rat medial
collateral ligament (MCL) injury model, and performed biomechanical testing 14 days
post-injury [31]. The MCL was not subject to primary repair in this model. Based on
these findings, we postulate that at three weeks post-injury, the tensile strength of the
tendon repair was predominantly due to the tensile strength of the 6-0 polypropylene
suture repair. Wang et al. found that ultimate stress and maximum loading were signifi-
cantly increased in the exosome treated group compared with injury; however, they did
not compare TSCs to TSC-derived EVs regarding biomechanics [34]. Only TSC versus
phosphate-buffered saline (PBS) and EVs versus PBS were compared, raising the possibility
of reporting bias. No included studies reported stem cells versus EVs. For those studies
which did report EVs having a positive impact on the biomechanics of ligament/tendon,
the shortest follow-up time post-injury was four weeks. This might suggest that the effect
of EVs on healing is mostly realised beyond the four-week point. Studies with a larger
sample size and animals sacrificed at multiple time points to allow for biochemical and
biomechanical studies need to explore this hypothesis and plot a timeline for histological
and biomechanical improvement.
4.7. Limitations
One major limitation of this systematic review was the heterogeneity between studies
regarding outcome measures reported. The qualitative and quantitative evaluation of
tendon and ligament repair included macroscopic, histological, biochemical, and biome-
chanical analysis which differed widely between studies. Only six studies presented
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macroscopic analysis; all apart from Yao et al. [30] were qualitative in nature and therefore
subject to observer bias, making fair comparison between studies difficult. Similarly, al-
though many histological scoring systems were used, and while there was overlap in the
parameters they look for, this heterogeneity precluded any meta-analyses.
The majority of the analysis time points were done prior to four weeks after MSC-EV
application. This does not allow for long–term evaluations, which is especially important
for assessing animal mobility, whose evaluation can only be done after tissue integration
over time has taken place. Only Wang et al. performed longer-term analysis, at 18 weeks
after exosome injection [35].
The majority of the studies in this review were low risk, as determined by the SYRCLE
RoB assessment tool. Ten studies in this review had low bias; only Huang et al. had
some concern towards the risk of bias [32], with the main contributors being blinding
and detection bias. Nevertheless, only seven studies examined the specific cell surface
antigens of MSCs via flow cytometry, with four of them further performing a trilineage-
induced differentiation assay to identify the differentiation potential of MSCs. All studies
quantified EV dimensions and identified EV surface biomarkers, as stated in the Minimal
Information for Studies of Extracellular Vesicles (MISEV) criteria [23]. We suggest that all
future studies define their MSC-EV populations physically, biochemically, and functionally
by quantifiable features, as recommended by the International Society for Cellular Therapy
(ISCT) [22], utilise objective quantifiable methods for macroscopic and histological analysis,
and standardise MSC-EV delivery methods, based on the animal model used, and the ideal
volume and/or cell number for a given defect size.
5. Conclusions
Tendinopathy is a common disorder that results in a significant disease burden. Re-
generative approaches via tissue engineering are a promising option, especially novel
cell-free therapies utilising MSC-EVs, which have been shown to be effective in in vitro
studies. Randomised studies in suitable animal models that mimic human disease are
necessary before progression to human trials. In this review, all included in vivo studies
reported better tendon/ligament repair following MSC-EV treatment, but not all found
improvements in every parameter measured. Although biomechanical properties are very
relevant for assessing tendon and ligament healing, this was not consistently assessed.
Even if it was assessed, evidence linking biomechanical alterations to functional improve-
ment was weak; studies are needed that rigorously examine the underlying mechanisms
for the enhancement of biomechanical properties after MSC-EV treatment. The progression
of promising preclinical data to achieve successful clinical market authorisation remains
a bottleneck. One hurdle for progress to the clinic is the transition from small animal
research to advanced preclinical studies in large animals to test for the safety and efficacy
of products. However, it is likely that there will be translational questions not completely
answered by animal models as co-morbidities (e.g., obesity, smoking) will be challenging
to model. Nevertheless, the studies in this review have showcased the safety and efficacy
of MSC-EV therapy for tendon/ligament healing, by attenuating the initial inflammatory
response and accelerating tendon matrix regeneration, providing a basis for potential
clinical use in tendon/ligament repair.
We have given a rationale for the further development of a ready-to-use, cell-free,
MSC-based approach that is highly effective for tendon and ligament repair. Future studies
should focus on forming a link between histological, biochemical, and functional outcomes,
quantify macroscopic assessment of tendon repair, and standardise histological scoring
systems, whilst adhering to ISCT and MISEV guidelines for MSC-EV research.
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